Key result
MicroRNAs regulate key pathological processes in the obese heart, including remodeling, apoptosis, and inflammation.
Understanding the regulatory roles of microRNAs in obesity-related heart failure may inform the development of novel RNA-based therapeutic strategies.
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, driven by diverse pathophysiological mechanisms. Among its major risk factors, obesity has emerged as a lobal public health concern affecting individuals across all age groups. The rising prevalence of obesity significantly increases the risk of cardiovascular complications, including the development and progression of HF. MicroRNAs (miRNAs), small non-coding RNA molecules, have garnered attention for their regulatory roles in cardiovascular disease, particularly through post-transcriptional modulation of gene expression. This review highlights the involvement of miRNAs in key pathological processes observed in the obese heart, including cardiac remodeling, apoptosis, angiogenesis, inflammation, mitochondrial dysfunction, and myocardial lipotoxicity. Understanding how specific miRNAs and their targets contribute to HF in the context of obesity may inform the development of novel RNA-based therapeutic strategies for cardiometabolic disease.
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2025) conducted a review in Heart failure and obesity. MicroRNAs (miRNAs) was evaluated. MicroRNAs play a regulatory role in key pathological processes in the obese heart, including cardiac remodeling, apoptosis, inflammation, and mitochondrial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: